3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
7
Gastrointestinal
4
Tumor-Agnostic
3
Dermatologic
2
Breast
2
Sarcoma
1
NET
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Conditions
Ovarian Neoplasms
15
Uterine Cervical Neoplasms
12
Carcinoma, Ovarian Epithelial
10
Fallopian Tube Neoplasms
8
Endometrial Neoplasms
7
Peritoneal Neoplasms
4
Colorectal Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Recurrence
2
Uterine Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Stomach Neoplasms
1
Shoulder Impingement Syndrome
1
Sarcoma
1
Pregnancy Complications
1
Postoperative Complications
1
Pelvic Neoplasms
1
Patient Satisfaction
1
Pain, Postoperative
1
Ovarian Germ Cell Cancer
1
Ovarian Cysts
1
Neoplasms
1
Neoplasm Metastasis
1
Myofibroma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Leiomyoma
1
Infertility, Female
1
Interventions
pembrolizumab
23
Paclitaxel
14
Cyclophosphamide
13
Carboplatin
12
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
9
fludarabine
8
Nivolumab
7
Leucovorin
7
Gemcitabine
7
Fluorouracil
7
Doxorubicin
7
aldesleukin
6
Oxaliplatin
6
Cisplatin
6
liposomal doxorubicin
5
Topotecan
5
Taxes
5
Irinotecan
5
Interleukin-2
5
olaparib
4
atezolizumab
4
Hyperthermic Intraperitoneal Chemotherapy
4
Drug Therapy
4
seribantumab
3
fludarabine phosphate
3
durvalumab
3
dostarlimab
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Surgical Procedures, Operative
×
Gynecologic
×
Clear all
NCT05081609
2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2
Active not recruiting
320 enrolled